{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:26:00Z","timestamp":1790886360450,"version":"4.1.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>Mesonephric adenocarcinoma (MA) of the cervix and mesonephric-like adenocarcinoma (MLA) of the endometrium and ovaries are rare, aggressive tumors showing limited response to standard therapy. The DESTINY-PanTumor02 study demonstrated strong responses to Trastuzumab Deruxtecan (T-Dxd), an antibody-drug conjugate targeting HER2, in multiple HER2+ chemoresistant tumors, including gynecologic carcinomas. Mirvetuximab soravtansine (MIRV), which targets folate receptor-1 (FOLR1), is FDA-approved for platinum-resistant tubo-ovarian cancers with \u226575% moderate\/strong staining, and emerging studies show meaningful responses to MIRV combination therapy even at lower FOLR1 expression. The National Comprehensive Cancer Network (NCCN) also recommends T-Dxd as second-line therapy for recurrent HER2 (2\u20133+) endometrial carcinoma. However, these biomarkers have not been adequately evaluated in MA\/MLA. We assessed HER2 and FOLR1 immunohistochemical expression in 21 MA\/MLA cases (13 endometrial, 5 ovarian, 3 cervical). HER2 was scored using endometrial cancer guidelines (EC) and American Society of Clinical Oncology\/College of American Pathologists (ASCO\/CAP) gastric\/gastroesophageal criteria (GaC). FOLR1 scoring followed MIRV eligibility thresholds. HER2 expression was present in 14\/21 tumors; HER2 (2+) was seen in two cases by both criteria, with no HER2 (3+) identified. The other 12 cases showed HER2 (1+) by EC criteria, while only four met 1+ by GaC criteria. FOLR1 met current MIRV treatment criteria in one case, while ten others showed expression ranging from 5% to 70%. Although most tumors did not meet current biomarker thresholds for Trastuzumab or MIRV monotherapy, detectable expression supports exploring anti-HER2 T-Dxd and MIRV combination treatments in selected MA\/MLA cases.<\/jats:p>","DOI":"10.1097\/pgp.0000000000001187","type":"journal-article","created":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T10:01:14Z","timestamp":1778148074000},"page":"349-357","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["HER2 and FOLR1 Expression in Mesonephric and Mesonephric-Like Adenocarcinomas in the Gynecologic Tract"],"prefix":"10.1097","volume":"45","author":[{"given":"Eyas","family":"Alzayadneh","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Virginia, Charlottesville, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan E.","family":"Dibbern","sequence":"additional","affiliation":[{"name":"Department of Pathology, Emory School of Medicine, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Rabban","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of California San Francisco, San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluwole","family":"Fadare","sequence":"additional","affiliation":[{"name":"Department of Pathology, University California San Diego, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"Mills","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Virginia, Charlottesville, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,5,7]]},"reference":[{"key":"R1-20260813","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/his.12895","article-title":"Hormone receptor-negative, thyroid transcription factor 1-positive uterine and ovarian adenocarcinomas: report of a series of mesonephric-like adenocarcinomas","volume":"68","author":"McFarland","year":"2016","journal-title":"Histopathology"},{"key":"R2-20260813","doi-asserted-by":"crossref","first-page":"698","DOI":"10.3390\/jcm10040698","article-title":"Mesonephric-like adenocarcinoma of the endometrium: diagnostic advances to spot this wolf in sheep\u2019s clothing. A review of the literature","volume":"10","author":"Deolet","year":"2021","journal-title":"J Clin Med"},{"key":"R3-20260813","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/PAS.0000000000001873","article-title":"Mesonephric-like endometrial carcinoma: results from immunohistochemical screening of 300 endometrial carcinomas and carcinosarcomas for this often overlooked and potentially aggressive entity","volume":"46","author":"Mills","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"R4-20260813","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/s41379-021-00799-6","article-title":"Mesonephric and mesonephric-like carcinomas of the female genital tract: molecular characterization including cases with mixed histology and matched metastases","volume":"34","author":"da Silva","year":"2021","journal-title":"Mod Pathol"},{"key":"R5-20260813","doi-asserted-by":"crossref","first-page":"100652","DOI":"10.1016\/j.gore.2020.100652","article-title":"Molecular profiling of mesonephric and mesonephric-like carcinomas of cervical, endometrial and ovarian origin","volume":"34","author":"Lin","year":"2020","journal-title":"Gynecol Oncol Rep"},{"key":"R6-20260813","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/PGP.0000000000001150","article-title":"Mesonephric-like adenocarcinoma (MLA) diagnostic criteria and controversies: perspectives and guidance from pathologists in the MLA consortium","volume":"45","author":"Mills","year":"2026","journal-title":"Int J Gynecol Pathol"},{"key":"R7-20260813","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/PAS.0000000000001612","article-title":"Clinicopathologic characteristics of mesonephric adenocarcinomas and mesonephric-like adenocarcinomas in the gynecologic tract: a multi-institutional study","volume":"45","author":"Pors","year":"2021","journal-title":"Am J Surg Pathol"},{"key":"R8-20260813","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","article-title":"Randomized phase II trial of carboplatin\u2013paclitaxel compared with carboplatin\u2013paclitaxel\u2013trastuzumab in advanced (stage III\u2013IV) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): updated overall survival analysis","volume":"26","author":"Fader","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R10-20260813","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JCO.23.02005","article-title":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial","volume":"42","author":"Meric-Bernstam","year":"2024","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"R13-20260813","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"R14-20260813","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1158\/1078-0432.CCR-23-0991","article-title":"FDA approval summary: mirvetuximab soravtansine-gynx for FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"29","author":"Dilawari","year":"2023","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"R16-20260813","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1056\/NEJMoa2309169","article-title":"Mirvetuximab soravtansine in FR\u03b1-positive, platinum-resistant ovarian cancer","volume":"389","author":"Moore","year":"2023","journal-title":"N Engl J Med"},{"key":"R17-20260813","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology","volume":"35","author":"Bartley","year":"2017","journal-title":"J Clin Oncol"},{"key":"R18-20260813","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2017.08.015","article-title":"Characterization of folate receptor alpha (FR\u03b1) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FR\u03b1-targeting antibody-drug conjugate mirvetuximab soravtansine","volume":"147","author":"Martin","year":"2017","journal-title":"Gynecol Oncol"},{"key":"R19-20260813","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3390\/jcm14010117","article-title":"The clinical characteristics and treatment outcomes of mesonephric tumours of the uterine cervix: a systematic review and proposal of embryologically-oriented surgical resection","volume":"14","author":"Daas","year":"2025","journal-title":"J Clin Med"},{"key":"R20-20260813","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.gore.2016.05.002","article-title":"Mesonephric adenocarcinoma of the cervix: case report and literature review","volume":"17","author":"Dierickx","year":"2016","journal-title":"Gynecol Oncol Rep"},{"key":"R21-20260813","doi-asserted-by":"crossref","first-page":"284","DOI":"10.6004\/jnccn.2025.0038","article-title":"NCCN Guidelines\u00ae insights: uterine neoplasms, version 3.2025","volume":"23","author":"Abu-Rustum","year":"2025","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"R22-20260813","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.22.02558","article-title":"Trastuzumab deruxtecan for human epidermal growth factor receptor 2\u2013expressing advanced or recurrent uterine carcinosarcoma (NCCH1615): the STATICE trial","volume":"41","author":"Nishikawa","year":"2023","journal-title":"J Clin Oncol"},{"key":"R23-20260813","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ygyno.2018.07.017","article-title":"Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer","volume":"151","author":"Moore","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R24-20260813","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","article-title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer","volume":"170","author":"Gilbert","year":"2023","journal-title":"Gynecol Oncol"},{"key":"R28-20260813","doi-asserted-by":"crossref","first-page":"14700","DOI":"10.18632\/oncotarget.3739","article-title":"Assessment of folate receptor-\u03b2 expression in human neoplastic tissues","volume":"6","author":"Shen","year":"2015","journal-title":"Oncotarget"},{"key":"R29-20260813","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.bbrc.2017.08.015","article-title":"Folate receptor alpha is associated with cervical carcinogenesis and regulates cervical cancer cells growth by activating ERK1\/2\/c-Fos\/c-Jun","volume":"491","author":"Liu","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"R30-20260813","first-page":"567","article-title":"Folate receptor alpha expression in platinum resistant\/refractory ovarian carcinomas and primary endocervical adenocarcinomas","volume":"26","author":"Rubinsak","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol AIMM"},{"key":"R31-20260813","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.3802\/jgo.2022.33.e82","article-title":"High expression of folate receptor alpha is associated with poor prognosis in patients with cervical cancer","volume":"33","author":"Yazaki","year":"2022","journal-title":"J Gynecol Oncol"},{"key":"R32-20260813","first-page":"2042","article-title":"Mesonephric-like adenocarcinoma of the uterine corpus: comprehensive immunohistochemical analyses using markers for mesonephric, endometrioid and serous tumors","volume":"11","author":"Kim","year":"2021","journal-title":"Diagn Basel Switz"},{"key":"R33-20260813","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s13048-024-01383-7","article-title":"Mesonephric-like adenocarcinoma of the ovary","volume":"17","author":"Yang","year":"2024","journal-title":"J Ovarian Res"},{"key":"R34-20260813","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.3390\/curroncol31090378","article-title":"Ovarian mesonephric-like adenocarcinoma: its prevalence in a Japanese high-volume cancer center and a literature review on therapeutic targets","volume":"31","author":"Ogawa","year":"2024","journal-title":"Curr Oncol"},{"key":"R35-20260813","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/PAS.0000000000002392","article-title":"Comparison of HER2 scoring systems in endometrial cancer: toward optimization of HER2-directed therapies","volume":"49","author":"Menshikova","year":"2025","journal-title":"Am J Surg Pathol"}],"container-title":["International Journal of Gynecological Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/PGP.0000000000001187","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T13:01:14Z","timestamp":1786626074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/PGP.0000000000001187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,7]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/pgp.0000000000001187","relation":{},"ISSN":["0277-1691","1538-7151"],"issn-type":[{"value":"0277-1691","type":"print"},{"value":"1538-7151","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,7]]},"assertion":[{"value":"2026-02-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}